Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Paredes

Showing results (201-210 of 309) with videos related to

Pageof 31
Sort By:
Life Science Alliance|July 29, 2021
High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patientsMaría Luisa Rodríguez de la Concepción, Erola Ainsua-Enrich, Esteban Reynaga, et al.
AIDS Research and Human Retroviruses|August 12, 2020
A Summary of the Fifth Annual Virology Education HIV Microbiome WorkshopScott Sherrill-Mix, Kaleigh Connors, Grace M Aldrovandi, et al.
AIDS (London, England)|January 10, 2015
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapyJosé L Blanco, Julio S G Montaner, Vincent C Marconi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 13, 2025
Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trialJose M Miro, Ferran Torres, Christian Manzardo, et al.
Plos One|May 30, 2009
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivoAthe M N Tsibris, Bette Korber, Ramy Arnaout, et al.
Frontiers in Pharmacology|April 12, 2021
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing ScreenJordi Rodon, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, et al.
The Journal of Infectious Diseases|February 2, 2026
Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV ResearchSara Gianella, Adam Lauring, Roger Paredes, et al.
Plos One|September 28, 2017
Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-BMiriam Rosás-Umbert, Beatriz Mothe, Marc Noguera-Julian, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 23, 2025
Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort studyTomas O Jensen, Shweta Sharma, Anchalee Avihingsanon, et al.
The Lancet. Microbe|May 11, 2022
Yaws re-emergence and bacterial drug resistance selection after mass administration of azithromycin: a genomic epidemiology investigationMathew A Beale, Marc Noguera-Julian, Charmie Godornes, et al.
Pageof 31

Showing results (201-210 of 309) with videos related to

Sort By:
Pageof 31
Life Science Alliance|July 29, 2021
High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patientsMaría Luisa Rodríguez de la Concepción, Erola Ainsua-Enrich, Esteban Reynaga, et al.
AIDS Research and Human Retroviruses|August 12, 2020
A Summary of the Fifth Annual Virology Education HIV Microbiome WorkshopScott Sherrill-Mix, Kaleigh Connors, Grace M Aldrovandi, et al.
AIDS (London, England)|January 10, 2015
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapyJosé L Blanco, Julio S G Montaner, Vincent C Marconi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 13, 2025
Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trialJose M Miro, Ferran Torres, Christian Manzardo, et al.
Plos One|May 30, 2009
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivoAthe M N Tsibris, Bette Korber, Ramy Arnaout, et al.
Frontiers in Pharmacology|April 12, 2021
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing ScreenJordi Rodon, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, et al.
The Journal of Infectious Diseases|February 2, 2026
Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV ResearchSara Gianella, Adam Lauring, Roger Paredes, et al.
Plos One|September 28, 2017
Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-BMiriam Rosás-Umbert, Beatriz Mothe, Marc Noguera-Julian, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 23, 2025
Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort studyTomas O Jensen, Shweta Sharma, Anchalee Avihingsanon, et al.
The Lancet. Microbe|May 11, 2022
Yaws re-emergence and bacterial drug resistance selection after mass administration of azithromycin: a genomic epidemiology investigationMathew A Beale, Marc Noguera-Julian, Charmie Godornes, et al.
Pageof 31